Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Avinash Phadke	09/05/2007
Xiangzhu Wang	09/05/2007
Suoming Zhang	09/05/2007
Atul Agarwal	09/05/2007

RECEIVING PARTY DATA

Name:	Achillion Pharmaceuticals, Inc.
Street Address:	300 George Street
City:	New Haven
State/Country:	CONNECTICUT
Postal Code:	06511

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	11777745

CORRESPONDENCE DATA

Fax Number: (860)286-0115

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 860-286-2929

Email: jdesousa@cantorcolburn.com
Correspondent Name: CANTOR COLBURN, LLP

Address Line 1: 20 Church Street

Address Line 2: 22nd Floor

Address Line 4: Hartford, CONNECTICUT 06103

ATTORNEY DOCKET NUMBER: API-0028

NAME OF SUBMITTER: Leslie-Anne Maxwell

Total Attachments: 2

500675488

PATENT REEL: 021680 FRAME: 0973 H \$40.00

CH \$40

source=25P9749#page1.tif source=25P9749#page2.tif

> PATENT REEL: 021680 FRAME: 0974

ASSIGNMENT

WHEREAS We, Avinash Phadke of 51 Gilbert Lane, Branford, Connecticut, in the County of New Haven; Xiangzhu Wang of 4 Brushy Plain Road, Apt. #224, Branford, Connecticut, in the County of New Haven; and Suoming Zhang of 22 Dream Lake Drive, Madison, Connecticut, in the County of New Haven; Atul Agarwal of 75 Nicholas Court, Hamden, Connecticut, in the County of New Haven; (hereinafter "ASSIGNORS") have invented certain new and useful improvements in:

4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION

which claims priority from U.S. Provisional Patent Application No. 60/830,488 filed on July 13, 2006 and U.S. Provisional Patent Application No. 60/945,786 filed on June 22, 2007;

AND WHEREAS, ACHILLION PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware, having a place of business at 300 George Street, New Haven, Connecticut 06511, is desirous of acquiring an interest in the United States and all foreign countries, in and to the said invention and Letters Patent to be obtained therefore;

NOW THEREFORE, TO ALL WHOM IT MAY CONCERN, be it known that, for good and sufficient consideration the, receipt of which is hereby acknowledged, We, the said ASSIGNORS; have sold, assigned, and transferred, and by these presents do sell, assign and transfer unto the said ACHILLION PHARMACEUTICALS, INC., the entire right, title and interest in and to said invention in the United States and in all foreign countries, including priority rights, as fully set forth and described in said application; and We do hereby authorize and request the Commissioner of Patents to issue said Letters Patent on said application, and any and all Letters Patent that may be issued upon any and all revivals, refilings, continuations, continuations-in-part, divisions and reissues thereof, to the said ACHILLION PHARMACEUTICALS, INC., an assignee of the entire right, title and interest in and to the same, for the sole use and behoof of ACHILLION PHARMACEUTICALS, INC., its successors and assigns; and We do hereby agree that the said ACHILLION PHARMACEUTICALS, INC., may apply for foreign Letters Patent on said invention and that We will execute all papers necessary in connection with the United States and foreign applications when called upon to do so by the said ACHILLION PHARMACEUTICALS, INC., its successors or assigns, and that We will, at the cost and expense of the said ACHILLION PHARMACEUTICALS, INC., fully assist and cooperate in all matters in connection with the United States and foreign applications and patents issuing thereon.

> PATENT REEL: 021680 FRAME: 0975

The undersigned declare that all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 95107

18 hadle L.S

Date: 9/5/07

Harfly wes L.S.

Date: 9/5/57

Suoming Zhang

L.S.

Date: 9/5/07

Atul Agarwal

2